Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.34 |
| ▸ | BCL2L11 | O43521 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26194443 | 0.90 | KDM1A (0.45) | KDM1ASIGMAR1SRD5A1KDM4CCYP2C19 | |
| SCHEMBL17542361 | 0.88 | KDM1A (0.44) | KDM1ASIGMAR1SRD5A1KDM4CMCL1 | |
| SCHEMBL17542359 | 0.88 | KDM1A (0.44) | KDM1ASIGMAR1SRD5A1KDM4CMCL1 | |
| SCHEMBL17542298 | 0.88 | KDM1A (0.44) | KDM1ASIGMAR1SRD5A1KDM4CMCL1 | |
| SCHEMBL26314795 | 0.83 | KDM1A (0.38) | KDM1ASIGMAR1SRD5A1KDM4CMCL1 | |
| SCHEMBL23443007 | 0.82 | KDM1A (0.48) | KDM1ASIGMAR1SRD5A1KDM4CMCL1 | |
| SCHEMBL23442105 | 0.75 | KDM1A (0.39) | KDM1ASIGMAR1SRD5A1KDM4CMCL1 | |
| SCHEMBL25643125 | 0.74 | SLC6A15 (0.38) | KDM1AKDM4C | |
| SCHEMBL26194433 | 0.74 | KDM1A (0.48) | KDM1ASIGMAR1SRD5A1KDM4CMAP3K14 | |
| SCHEMBL19285835 | 0.73 | KDM1A (0.40) | KDM1ASIGMAR1SRD5A1KDM4CMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9562061-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | MCL1, BAK1, BCL3 | KDM1A 563/4885SIGMAR1 4148/4885SRD5A1 4078/4885 |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL2L1, BCL9 | KDM1A 1335/4885SIGMAR1 4291/4885SRD5A1 4061/4885 |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | KDM1A 1335/4885SIGMAR1 4291/4885SRD5A1 4061/4885 |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | KDM1A 1335/4885SIGMAR1 4291/4885SRD5A1 4061/4885 |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | KDM1A 1212/4885SIGMAR1 4041/4885SRD5A1 4195/4885 |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | KDM1A 1212/4885SIGMAR1 4041/4885SRD5A1 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.